{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(1)"],"submitter":["Prasad V"],"funding":["Arnold Ventures"],"pubmed_abstract":["<h4>Background</h4>Rank preserving structural failure time (RPSFT) is a statistical method to correct or adjust for crossover in clinical trials, by estimating the counterfactual effect on overall survival (OS) when control arm patients do not receive the interventional drug when their tumor progresses. We sought to examine the strength of correlation between differences in uncorrected and corrected OS hazard ratios and percentage of crossover, and characterize instances of fundamental and sequential efficacy.<h4>Methods</h4>In a cross-sectional analysis (2003-2023), we reviewed oncology randomized trials that used RPSFT analysis to adjust the OS hazard ratio for patients who crossed over to an anti-cancer drug. We calculated the percentage of RPSFT studies evaluating a drug for fundamenta"],"journal":["Trials"],"pagination":["373"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10239129"],"repository":["biostudies-literature"],"pubmed_title":["Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use."],"pmcid":["PMC10239129"],"pubmed_authors":["Prasad V","Haslam A","Kim MS"],"additional_accession":[]},"is_claimable":false,"name":"Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use.","description":"<h4>Background</h4>Rank preserving structural failure time (RPSFT) is a statistical method to correct or adjust for crossover in clinical trials, by estimating the counterfactual effect on overall survival (OS) when control arm patients do not receive the interventional drug when their tumor progresses. We sought to examine the strength of correlation between differences in uncorrected and corrected OS hazard ratios and percentage of crossover, and characterize instances of fundamental and sequential efficacy.<h4>Methods</h4>In a cross-sectional analysis (2003-2023), we reviewed oncology randomized trials that used RPSFT analysis to adjust the OS hazard ratio for patients who crossed over to an anti-cancer drug. We calculated the percentage of RPSFT studies evaluating a drug for fundamenta","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-04T23:05:59.134Z","creation":"2025-04-04T23:05:59.134Z"},"accession":"S-EPMC10239129","cross_references":{"pubmed":["37270500"],"doi":["10.1186/s13063-023-07412-y"]}}